Next Article in Journal
Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy
Next Article in Special Issue
Socioeconomic Deprivation and Invasive Breast Cancer Incidence by Stage at Diagnosis: A Possible Explanation to the Breast Cancer Social Paradox
Previous Article in Journal
New Insights into YAP/TAZ-TEAD-Mediated Gene Regulation and Biological Processes in Cancer
 
 
Article
Peer-Review Record

Financial Toxicity in Swiss Cancer Patients Treated with Proton Therapy: An Observational Cross-Sectional Study on Self-Reported Outcome

Cancers 2023, 15(23), 5498; https://doi.org/10.3390/cancers15235498
by Barbara Bachtiary 1,*, Leonie Grawehr 2, Filippo Grillo Ruggieri 1, Ulrike Held 3 and Damien C. Weber 1,2,4,5
Reviewer 2: Anonymous
Cancers 2023, 15(23), 5498; https://doi.org/10.3390/cancers15235498
Submission received: 25 September 2023 / Revised: 10 November 2023 / Accepted: 15 November 2023 / Published: 21 November 2023
(This article belongs to the Special Issue Disparities in Cancer Prevention, Screening, Diagnosis and Management)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

This is a well written paper on financial toxicity in cancer patients receiving proton therapy.  The intro, methods, and results are clear and well written.  I do feel that more discussion about limitations and its impact on recommendations could be added.   Included in this is the potential effect of selection bias (those unable to afford treatment/do not seek treatment and therefore not included in this study).  As a consequence it is possible this sample is NOT representative of the full eligible population.   I have provided further details in my attached marked up PDF document.

Comments for author File: Comments.pdf

Comments on the Quality of English Language

Well written with only a few minor suggestions in attached document.

Author Response

Please see the attachment. 

Author Response File: Author Response.docx

Reviewer 2 Report

Comments and Suggestions for Authors

Thanks for inviting to review this paper. I think the paper is good. I suggest for the authors to add other variables available to them for mulvar. analysis

my comments:

1. abstract - estimates -- add 95CI

2. M&M - a large number of patients declined to participate. is this systematic? please comment and analyse if possible.

3. significant number also don't speak the languages - are they immigrants? comment. this may cause systematic exclusion.

4. Please reanalyse with site of tx, chemo and treatment duration as explanatory variables

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

Comments and Suggestions for Authors

I am satisfied with the responses to my questions/concerns.  I have no further comments.

Reviewer 2 Report

Comments and Suggestions for Authors

Accept 

Back to TopTop